ZA200903578B - Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone - Google Patents

Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Info

Publication number
ZA200903578B
ZA200903578B ZA200903578A ZA200903578A ZA200903578B ZA 200903578 B ZA200903578 B ZA 200903578B ZA 200903578 A ZA200903578 A ZA 200903578A ZA 200903578 A ZA200903578 A ZA 200903578A ZA 200903578 B ZA200903578 B ZA 200903578B
Authority
ZA
South Africa
Prior art keywords
pyridin
methanone
triazol
chlorophenyl
trifluoromethyl
Prior art date
Application number
ZA200903578A
Other languages
English (en)
Inventor
Michael Edward Kobierski
Michael E Kopach
Pingyun Chen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA200903578B publication Critical patent/ZA200903578B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200903578A 2006-12-20 2009-05-22 Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone ZA200903578B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87085106P 2006-12-20 2006-12-20

Publications (1)

Publication Number Publication Date
ZA200903578B true ZA200903578B (en) 2010-07-28

Family

ID=39273082

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903578A ZA200903578B (en) 2006-12-20 2009-05-22 Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Country Status (22)

Country Link
US (4) US8772496B2 (ja)
EP (1) EP2121610B1 (ja)
JP (1) JP5443168B2 (ja)
KR (1) KR20090081028A (ja)
CN (1) CN101568523A (ja)
AU (1) AU2007337255A1 (ja)
BR (1) BRPI0721069A2 (ja)
CA (1) CA2671770C (ja)
DK (1) DK2121610T3 (ja)
EA (1) EA200970604A1 (ja)
EC (1) ECSP099441A (ja)
ES (1) ES2471990T3 (ja)
HR (1) HRP20140613T1 (ja)
IL (1) IL198775B (ja)
MX (1) MX2009006636A (ja)
NO (1) NO20092370L (ja)
PL (1) PL2121610T3 (ja)
PT (1) PT2121610E (ja)
RS (1) RS53386B (ja)
SI (1) SI2121610T1 (ja)
WO (1) WO2008079600A1 (ja)
ZA (1) ZA200903578B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200970604A1 (ru) * 2006-12-20 2009-10-30 Эли Лилли Энд Компани Новое промежуточное соединение и способ, используемый для получения {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
RU2770050C2 (ru) 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
US10287287B2 (en) 2015-08-17 2019-05-14 Eli Lilly And Company Process development of a pyridine-containing NK-1 receptor antagonist
US11549147B2 (en) 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
CN111343981A (zh) 2017-11-17 2020-06-26 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US20230145932A1 (en) * 2020-03-26 2023-05-11 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
WO2024138040A1 (en) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040600A1 (es) * 2002-04-26 2004-09-15 Lilly Co Eli Derivados de triazol como antagonistas del receptor de taquicinina
DE602004026333D1 (de) * 2003-10-24 2010-05-12 Lilly Co Eli NEUE KRISTALLINE FORMEN VON ä2-Ä1-(3,5-BISTRIFLUORMETHYLBENZYL)-5-PYRIDIN-4-YL-1H-Ä1,2,3ÜÜTRIAZOL-4-YLÜ-PYRIDIN-3-YLü-(2-CHLORPHENYL)METHANON
WO2006083711A1 (en) * 2005-02-01 2006-08-10 Eli Lilly And Company Tachykinin receptor antagonists
EA200970604A1 (ru) * 2006-12-20 2009-10-30 Эли Лилли Энд Компани Новое промежуточное соединение и способ, используемый для получения {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона

Also Published As

Publication number Publication date
NO20092370L (no) 2009-09-16
US20160060250A1 (en) 2016-03-03
EP2121610B1 (en) 2014-04-02
JP5443168B2 (ja) 2014-03-19
MX2009006636A (es) 2009-06-30
BRPI0721069A2 (pt) 2014-02-04
CA2671770C (en) 2015-09-15
SI2121610T1 (sl) 2014-08-29
ES2471990T3 (es) 2014-06-27
KR20090081028A (ko) 2009-07-27
US20170283394A1 (en) 2017-10-05
HRP20140613T1 (hr) 2014-08-15
IL198775A0 (en) 2010-02-17
PL2121610T3 (pl) 2014-09-30
JP2010513546A (ja) 2010-04-30
US10035787B2 (en) 2018-07-31
EP2121610A1 (en) 2009-11-25
US9708291B2 (en) 2017-07-18
CA2671770A1 (en) 2008-07-03
US20140206877A1 (en) 2014-07-24
EA200970604A1 (ru) 2009-10-30
WO2008079600A1 (en) 2008-07-03
US20100056795A1 (en) 2010-03-04
IL198775B (en) 2018-08-30
RS53386B (en) 2014-10-31
AU2007337255A1 (en) 2008-07-03
CN101568523A (zh) 2009-10-28
ECSP099441A (es) 2009-07-31
PT2121610E (pt) 2014-06-25
DK2121610T3 (da) 2014-06-30
US8772496B2 (en) 2014-07-08

Similar Documents

Publication Publication Date Title
ZA200903578B (en) Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
HUS1800010I1 (hu) 4-Fenil-6-(2,2,2-trifluor-1-feniletoxi)pirimidin-alapú vegyületek és alkalmazási eljárásaik
IL178899A0 (en) [3.2.0] heterocyclic compounds and methods of using the same
IL200990A (en) 4'-o-isoindulin derivatives are converted, their vehicles and methods of use
AP1970A (en) Piperidine derivatives and their use as insecticides, acaricides, molluscicides or nematicides
IL192241A0 (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof
IL202293A0 (en) 1,(,3)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation
EP1878428A4 (en) 5-METHYL-2- (1H) -PYRIDONE SUBSTITUTED IN 1 BY A PHENYL GROUP IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF ORGAN OR TISSUE FIBROSIS
IL179589A0 (en) Injection port and method of making the same
IL184503A0 (en) Pyrazole derivatives for the inhibition of cdk's and gsk's
EP1831170A4 (en) SUBSTITUTED AMINOPYRIDINES AND THEIR USE
GB2412239B (en) Ferroelectric capacitor hydrogen barriers and methods for fabricating the same
EP1932833A4 (en) NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
HK1087512A1 (en) Authenticity verification of articles
EP1717231A4 (en) SUBSTITUTED AZOLEO COMPOUND AND CORRESPONDING PREPARATION AND APPLICATION
HK1101811A1 (en) Article, filter media and method of making the filter media
ZA200800542B (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
ZA200705611B (en) Pyrazole derivatives for the inhibition of CDK'S and GSK'S
PL1890695T3 (pl) Zastosowanie 2,5-dipodstawionych pochodnych tiazol-4-onu w lekach
EP1734005A4 (en) TANTALIUM OXIDE AND / OR NIOBIUM OXIDE AND PROCESS FOR THE PREPARATION THEREOF
PL376122A1 (pl) Sposób wytwarzania rekombinowanej szczepionki przeciwko krwotocznej chorobie królików, szczepionka oraz zastosowanie antygenu rekombinowanego białka do wytwarzania szczepionki
ZA200806876B (en) Crystal form of besipirdine chlorhydrate, process preparation and use thereof
PL374411A1 (pl) Nowe związki, pochodne 1,3,5-triazyny oraz sposób wytwarzania nowych związków, pochodnych 1,3,5-triazyny
IT1391960B1 (it) Procedimento per la realizzazione, a pie' d'opera o in opera, di giunti strutturali mono e/o plurivie.
GB0318446D0 (en) Improvements in or relating to calenders